Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic ...

A phase 3 trial shows that ivarmacitinib improves symptoms in adults with moderate to severe atopic dermatitis compared with ...

Shares of Regeneron Pharmaceuticals are trading higher Wednesday recovering after a drop on Tuesday that followed the release ...

Shares of Regeneron Pharmaceuticals Inc. REGN advanced 5.25% to $598.76 Wednesday, on what proved to be an all-around ...

Starting in 2025, the Eylea franchise as a whole began to decline due to competitive pressure from long-acting Vabysmo, which competes with Eylea HD, and Pabvlu, a biosimilar version of the original ...

Neoadjuvant immunotherapy alone resulted in significant treatment response among most patients with mismatch-repair-deficient ...

Currently, EYLEA HD is approved for dosing intervals of 8-16 weeks for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). For patients with diabetic ...

The FDA does not plan a reorganization of the agency but will consolidate offices that handle travel and IT ...

Nucor Corp.’s (NUE) shares rose 1.9% after the company reported first-quarter 2025 adjusted earnings per share of $0.77, surpassing the Zacks Consensus Estimate of $0.68. Shares of Regeneron ...

Researchers found hundreds of genes linked to osteoarthritis, opening doors to new and repurposed treatments. The findings ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

MML Investors Services ramped up its Regeneron stake by 41.7%, acquiring 2,218 additional shares during Q4. This brings their ...